Dataset Information
Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials.
Ontology highlight
ABSTRACT: Objective(s)
Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored.Methods
Medline, Embase and Web of Science were searched to March 8, 2014 for prospective, randomized controlled trials (RCTs) that assessed the safety profile of edoxaban with warfarin. Safety outcomes examined included bleeding risk and mortality.Results
Five trials including 31,262 patients that met the inclusion criteria were pooled. Overall, edoxaban was associated with a significant decrease in major or clinically relevant nonmajor bleeding events [risk ratio (RR) 0.78, 95% confidence interval (CI) 0.74 to 0.82, p<0.001] and any bleeding events [RR 0.82, 95% CI 0.79 to 0.85, p<0.001]. Edoxaban also showed superiority to warfarin both in all-cause mortality [RR 0.92, 95% CI 0.85 to 0.99, p?=?0.02] and cardiovascular mortality [RR 0.87, 95% CI 0.79 to 0.96, p?=?0.004]. Subgroup analyses indicated that RRs of edoxaban 30, 60 or 120 mg/d were 0.67 (p<0.001), 0.87 (p<0.001) and 3.3 (p?=?0.004) respectively in major or clinically relevant nonmajor bleeding; 0.71 (p<0.001), 0.89 (p<0.001) and 2.29 (p?=?0.002) respectively in any bleeding; as well as 0.86 (p?=?0.01), 0.87 (p?=?0.01) and 0.28 (p?=?0.41) respectively in cardiovascular death… Meanwhile, paramount to note that pooled results other than the largest trial showed edoxaban was still associated with a decrease in the rate of major or clinically relevant nonmajor bleeding event (p?=?0.02) and any bleeding (p?=?0.002), but neither in all-cause death (p?=?0.66) nor cardiovascular death (p?=?0.70).Conclusions
Edoxaban, a novel orally available direct factor Xa inhibitor, seems to have a favorable safety profiles with respect to bleeding risk and non-inferior in mortality when compared to warfarin. Further prospective RCTs are urgently needed to confirm the results of this meta-analysis.
SUBMITTER: Li S
PROVIDER: S-EPMC3988190 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
Publications
Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials.
PloS one 20140415 4
<h4>Objective(s)</h4>Edoxaban, a factor Xa inhibitor, is a new oral anticoagulant that has been developed as an alternative to vitamin K antagonists. However, its safety remains unexplored.<h4>Methods</h4>Medline, Embase and Web of Science were searched to March 8, 2014 for prospective, randomized controlled trials (RCTs) that assessed the safety profile of edoxaban with warfarin. Safety outcomes examined included bleeding risk and mortality.<h4>Results</h4>Five trials including 31,262 patients ...[more]